Navigation Links
Effective, safe anthrax vaccine can be grown in tobacco plants

Enough anthrax vaccine to inoculate everyone in the United States could be grown inexpensively and safely with only one acre of tobacco plants, a University of Central Florida molecular biologist has found.

Mice immunized with a vaccine produced in UCF professor Henry Daniell's laboratory through the genetic engineering of tobacco plants survived lethal doses of anthrax administered later by National Institutes of Health researchers. The results of the NIH-funded study are featured in the December issue of the Infection & Immunity journal.

Daniell's research is a breakthrough in efforts to find a safe and effective method of producing large quantities of vaccine for anthrax, one of the top bioterrorism threats facing the United States. The new production method also could help the government and health care providers avoid supply shortages, as one acre of plants can produce 360 million doses in a year.

"Anthrax vaccine is very much in need, primarily because of bioterrorism concerns," Daniell said. "But in the United States, only one company has the capacity to produce the vaccine, and it is made in very small quantities by fermentation. We can provide enough doses of a safe and effective vaccine for all Americans from just one acre of tobacco plants."

Current production of the vaccine involves an expensive fermentation process that can cause harmful side effects such as inflammation, flu-like symptoms and rashes. This has prompted some people to refuse to be vaccinated.

Seeking a safer and more effective alternative, Daniell and his colleagues injected the vaccine gene into the chloroplast genome of tobacco cells, partly because those plants grow much faster than carrots, tomatoes and coffee. They grew the cells for several weeks in Daniell's laboratory. Tests showed the vaccine taken from the plants was just as potent as the one produced through fermentation but lacks the bacterial toxin that can cause harmful side effect
'"/>

Source:University of Central Florida


Page: 1 2 3

Related biology news :

1. Scientists seek answers on what activates deadly anthrax spores
2. Antibodies from plants protect against anthrax
3. Defensins neutralize anthrax toxin
4. Critical step traced in anthrax infection
5. US Army plans to bulk-buy anthrax
6. New antibody shows promise as cure for anthrax
7. UCSD study finds anthrax toxins also harmful to fruit flies
8. Driver of anthrax toxicity could lead to late-stage therapy
9. Scientists design potent anthrax toxin inhibitor
10. Newly discovered protein kills anthrax bacteria by exploding their cell walls
11. Combating anthrax: Results of study published this month as researchers look for a better vaccine

Post Your Comments:
(Date:11/4/2009)...r 4, 2009 Childhood obesity in the United States ...ne fourth of advertising on daytime and prime time...tinuing questions about the role television plays ... of the Journal of Nutrition Education and Behavi...n might be a large contributor to the problem. , ...
(Date:11/4/2009)...ry that deciphered the DNA codes, or genomes, of t...has joined The Genome 10K Project, an internationa...sequences on 10,000 species of animals for conduct...can not be achieved. , Participating in The Geno...the Nov. 5, 2009 issue of the Journal of Heredity...
(Date:11/4/2009)...lif., Oct. 19 Spectros, developer ... imaging devices which shed light on life-threaten...xclusive distribution deals for both its T-Stat...covered include Australia, New Zealand, The Nethe...taly, France, Spain, Portugal, Poland, Greece, Tur...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Spectros Signs New International Distribution Deals 2TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 1TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 2TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 3TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 4Organogenesis Launches Regenerative Medicine College Scholarship 48514 1Organogenesis Launches Regenerative Medicine College Scholarship 48514 2Organogenesis Launches Regenerative Medicine College Scholarship 48514 3Gene Can Dampen Chemo Drug Effectiveness 48510 1
...king part in protein folding to ensure cells funct...g molecular motions provides researchers with info...hem decipher the bases of certain diseases, such a...lecular motion gone awry. , In the past, researche...clusters to run simulations. Or they had to be con...
...that a direct interaction between vitamin D and a ...ng multiple sclerosis (MS). The research, publishe...enetics , suggests that vitamin D deficiency durin...isk of the offspring developing MS later in life. ...ndition affecting young adults. More than 85,000 p...
...YSE: CSC ) announced today that it is one of 12 ...pport Services Unrestricted contract by the Depart...(BTF). The indefinite-delivery/indefinite-quantity... solutions and task orders to meet the mission nee... has a three-year base period and two one-year opt...
Other Biology News:New open-source software permits faster desktop computer simulations of molecular motion 2New open-source software permits faster desktop computer simulations of molecular motion 3Genetic study shows direct link between vitamin D and MS susceptibility 'gene' 2Genetic study shows direct link between vitamin D and MS susceptibility 'gene' 3CSC Awarded Department of Defense Biometrics Contract 2
(Date:11/6/2009)...LLEY, Calif., Nov. 6 Calbiotech, I...ll Business Innovative Research (SBIR) Phase I con...al command. Under terms of the agreement, Calbiote...or the diagnosis of Dengue virus. ,, Dengue ...s a major threat to military forces deployed to tr...
(Date:11/5/2009)...URG, Md., Nov. 5 GenVec,...al results for the third quarter ended September 3...n ($0.04 per share) for the three months ended Sep...lion ($0.08 per share) in the comparable quarter o...09, GenVec,s net loss was $14.1 million ($0.15 per...
(Date:11/5/2009)...e Call on Thursday, November 5, 2009 at 4:30 p.m. ... 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceutic... OGXI ) today reported unaudited financial results...mber 30, 2009 and reviewed the Company,s highlight...ng consolidated results reflect the operations of ...
(Date:11/5/2009)..., CA, November 5, 2009 S...n using proprietary taste receptor-based technolog...ood, beverage, and ingredient supply industries, t...ncial results for the third quarter ended Septembe...ird quarter of 2009, compared to $4.0 million for ...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...raTag(TM) technology,s ability to ...ANCISCO, Calif., May 16 Monogram,Biosciences, Inc...,collaborators will present results on HERmark(TM)...o measure HER2 and predict response to,Herceptin(R... cancer at the,upcoming 44th ASCO Annual Meeting t...
...r Aqua Bounty to scale back commitment to i... TSX symbol: SBS, CALGARY, May 1...,(TSX:SBS), a biotechnology company developing a p... cardiovascular diseases, today announced that,its... shrimp feed additive,program, Aqua Bounty Technol...
...oration,announced today that it has enrolled and r... IIb trial with oral larazotide acetate, an inhibi...atment of patients with active,celiac disease (CD)...d,placebo-controlled study will evaluate the clini...lity of larazotide acetate in 106 active CD,subjec...
Other Biology Technology:Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 2Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 3Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 4Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 5SemBioSys provides update on shrimp feed additive, Immunosphere(TM) 2SemBioSys provides update on shrimp feed additive, Immunosphere(TM) 3Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease 2Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease 3
Cassette, Hind III from Takara Mirus Bio
Cassette, EcoR I from Takara Mirus Bio
EcoR I Adaptors from Promega
Cassette, Sal I from Takara Mirus Bio
Biology Products: